Role of metabolism and pharmacokinetic studies in the discovery of new drugs--present and future perspectives.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Xenobiotica; the fate of foreign compounds in biological systems

• Publication date

  1992-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3109/00498259209053137PMID 1455898
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bioanalytical data in decision making: discovery and development.

  1992cited by this paper
• Species differences in metabolism and pharmacokinetics: are we close to an understanding?

  1991cited by this paper
• Quantitative analysis by high-performance liquid chromatography atmospheric pressure chemical ionization mass spectrometry: The determination of the renin inhibitor CP-80,794 in human serum

  1991cited by this paper
• Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents.

  1991cited by this paper
• Design of a well-absorbed renin inhibitor.

  1991cited by this paper
• Pharmacokinetic Aspects of Antifungal Therapy

  1990cited by this paper
• Design of toxicokinetic studies.

  1990cited by this paper
• Discovery of fluconazole, a novel antifungal agent.

  1990cited by this paper
• Design and discovery in the development of long-acting renin inhibitors.

  1990cited by this paper
• Pharmacokinetic Screening of o-Naphthoquinone 5-Lipoxygenase Inhibitors

  1990cited by this paper
• Azido glycols: potent, low molecular weight renin inhibitors containing an unusual post scissile site residue.

  1989cited by this paper
• Effects of UK 69 578: a novel atriopeptidase inhibitor.

  1989cited by this paper
• Biotransformation of amlodipine. Identification and synthesis of metabolites found in rat, dog and human urine/confirmation of structures by gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry.

  1989cited by this paper
• A phased approach to drug development

  1989cited by this paper
• Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).

  1988cited by this paper
• The molecular biology of cytochrome P450s.

  1988cited by this paper
• Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.

  1988cited by this paper
• Metabolic synthesis of arylacetic acid antiinflammatory drugs from arylhexenoic acids. 2. Indomethacin.

  1987cited by this paper
• Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.

  1987cited by this paper
• Discovery and anticonvulsant activity of the potent metabolic inhibitor 4-amino-N-(2,6-dimethylphenyl)-3,5-dimethylbenzamide.

  1987cited by this paper
• Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.

  1986cited by this paper
• Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation.

  1986cited by this paper
• Peptides and related drugs: a review of their absorption, metabolism, and excretion.

  1986cited by this paper
• Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals

  1985cited by this paper
• The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450.

  1985cited by this paper
• Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans

  1985cited by this paper
• Radioenzymatic assay of angiotensin-converting enzyme inhibitors in plasma and urine.

  1985cited by this paper
• Pharmacokinetics and toxicity testing.

  1984cited by this paper
• A new class of angiotensin-converting enzyme inhibitors

  1980cited by this paper
• Biopharmaceutics and clinical pharmacokinetics: An introduction

  1980cited by this paper

• Drug metabolic stability in early drug discovery to develop potential lead compounds

  2021cites this paper
• Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-aryl-thiazole and 2-Aryl-4-benzoyl-imidazole for Improving Oral Bioavailability

  2011cites this paper
• Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-Aryl-Thiazole (SMART) and 2-Aryl-4-Benzoyl-Imidazole (ABI) for Improving Oral Bioavailability

  2011cites this paper
• Pharmacologically active metabolites of currently marketed drugs: potential resources for new drug discovery and development.

  2010cites this paper
• Improving Drug Design: Considerations for the Structural Modification Process

  2010cites this paper
• Structural Modifications of Drug Candidates: How Useful Are They in Improving Metabolic Stability of New Drugs? Part I: Enhancing Metabolic Stability

  2010cites this paper
• Structural Modifications of Drug Candidates: How Useful Are They in Improving PK Parameters of New Drugs? Part II: Drug Design Strategies

  2010cites this paper
• The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?

  2006cites this paper
• Screening for reactive intermediates and toxicity assessment in drug discovery.

  2006cites this paper
• Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.

  2004cites this paper
• Applied Pharmacokinetics in Drug Development

  2003cites this paper
• Lack of in Vitro – in Vivo Correlation of a Novel Investigational Anticancer Agent, SH 30

  2002cites this paper
• Optimization of metabolic stability as a goal of modern drug design

  2001cites this paper
• Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures

  2000cites this paper
• Early ADME in support of drug discovery: the role of metabolic stability studies.

  2000cites this paper
• Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures.

  2000cites this paper
• Absorption Characteristics of Sustained‐Release 4‐Aminopyridine (Fampridine SR) in Patients with Chronic Spinal Cord Injury

  2000cites this paper
• Methylprednisolone Disposition Kinetics in Patients with Acute Spinal Cord Injury

  1998cites this paper
• Report on Questionnaires about the Present and the New PK Guidelines of Japan to Companies in JPMA

  1997cites this paper
• A literature review looking at contemporary developments in antimicrobial agents, with special reference to applications in the field of podiatry

  1996cites this paper
• Application of metabolism and pharmacokinetic studies to the drug discovery process.

  1996cites this paper
• The influence of food on the absorption and metabolism of drugs: an update

  1996cites this paper
• Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics

  1996cites this paper
• Therapeutic Agents and Cytochrome P450

  1995cites this paper
• Considerations in the Design of Toxicokinetic Programs

  1995cites this paper
• The Use of In Vitro Metabolism Techniques in the Planning and Interpretation of Drug Safety Studies

  1995cites this paper
• Design of drugs through a consideration of drug metabolism and pharmacokinetics

  1994cites this paper
• Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses

  1994cites this paper
• Pharmacokinetic Considerations in Rational Drug Design

  1994cites this paper
• Assessment of the value of high-performance thin-layer chromatography for the detection and characterisation of drugs and metabolites in biological fluids.

  1993cites this paper
• Structure-based drug design: applications in immunopharmacology and immunosuppression.

  1993cites this paper
• Structure-based drug design: applications in immunopharmacology and immunosuppression.

  1993cites this paper
• Twenty years on: a review of the current practice of drug metabolism and pharmacokinetic studies in the pharmaceutical industry

  1992cites this paper
• Comment. Twenty years on: a review of the current practice of drug metabolism and pharmacokinetic studies in the pharmaceutical industry.

  1992cites this paper